Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Bevacizumab biosimilar by Innovent Biologics for Endometrial Cancer: Likelihood of Approval
Bevacizumab biosimilar is under clinical development by Innovent Biologics and currently in Phase II for Endometrial Cancer. According to GlobalData,...
Bevacizumab biosimilar by Innovent Biologics for Recurrent Respiratory Papillomatosis (Juvenile Laryngeal Papilloma or Laryngeal Papilloma): Likelihood of Approval
Bevacizumab biosimilar is under clinical development by Innovent Biologics and currently in Phase II for Recurrent Respiratory Papillomatosis (Juvenile Laryngeal...
Bevacizumab biosimilar by Samsung Bioepis for Gastric Cancer: Likelihood of Approval
Bevacizumab biosimilar is under clinical development by Samsung Bioepis and currently in Phase II for Gastric Cancer. According to GlobalData,...
Bevacizumab biosimilar by Zhejiang Teruisi Pharmaceutical for Colorectal Cancer: Likelihood of Approval
Bevacizumab biosimilar is under clinical development by Zhejiang Teruisi Pharmaceutical and currently in Phase I for Colorectal Cancer. According to...
Bevacizumab biosimilar by Biocad for Non-Small Cell Lung Cancer: Likelihood of Approval
Bevacizumab biosimilar is under clinical development by Biocad and currently in Phase III for Non-Small Cell Lung Cancer. According to...
Bevacizumab biosimilar by Shanghai Henlius Biotech for Hepatocellular Carcinoma: Likelihood of Approval
Bevacizumab biosimilar is under clinical development by Shanghai Henlius Biotech and currently in Phase II for Hepatocellular Carcinoma. According to...
Bevacizumab biosimilar by Bio-Thera Solutions for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
Bevacizumab biosimilar is under clinical development by Bio-Thera Solutions and currently in Phase I for Recurrent Glioblastoma Multiforme (GBM). According...